Compared with vehicle treatment, lenvatinib significantly inhibited tumor growth despite CD8+ T cell depletion; the antitumor activity of lenvatinib was reduced under these CD8+ T cell-depleted conditions. The gene discussed is CD8A; the disease is neoplasm.